在终末期肾病的HIV感染患者中通过血液透析清除多替拉韦。
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease.
作者信息
Moltó José, Graterol Fredzzia, Miranda Cristina, Khoo Saye, Bancu Ioana, Amara Alieu, Bonjoch Anna, Clotet Bonaventura
机构信息
Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Universitat Autónoma de Barcelona (UAB), Barcelona, Spain
Nephrology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
出版信息
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2564-6. doi: 10.1128/AAC.03131-15. Print 2016 Apr.
Data on dolutegravir removal by hemodialysis are lacking. To study this, we measured dolutegravir plasma concentrations in samples of blood entering and leaving the dialyzer and of the resulting dialysate from 5 HIV-infected patients with end-stage renal disease. The median dolutegravir hemodialysis extraction ratio was 7%. The dolutegravir concentrations after the dialysis session remained far above the protein-binding-adjusted inhibitory concentration. Our results show minimal dolutegravir removal by hemodialysis, with no specific dolutegravir dosage adjustments required in this setting. (This study is registered at ClinicalTrials.gov under registration number NCT02487706.).
关于血液透析清除多替拉韦的数据尚缺。为研究此问题，我们测定了5例终末期肾病的HIV感染患者透析器进血和回血样本以及透析液中多替拉韦的血浆浓度。多替拉韦的血液透析中位清除率为7%。透析结束后多替拉韦浓度仍远高于蛋白结合调整后的抑制浓度。我们的结果显示血液透析对多替拉韦的清除极少，在此情况下无需对多替拉韦进行特殊剂量调整。（本研究已在ClinicalTrials.gov注册，注册号为NCT02487706。）
Zotero 插件